Exelixis

Exelixis Gets the Patients Eventually
Exelixis Gets the Patients Eventually
Motley Fool
Exelixis
kidney cancer
renal cell carcinoma
Cabometyx
Flag link:
Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
CP Wire
Exelixis
clinical trials
Cabometyx
Tecentriq
Flag link:
Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
Exelixis
Cabometyx
Tecentriq
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Flag link:
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
CP Wire
Roche
Exelixis
Tecentriq
Cotellic
colorectal cancer
Flag link:
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Roche
Exelixis
Tecentriq
Cotellic
Flag link:
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
CP Wire
Exelixis
Invenra
cancer
Merck
drug development
Flag link:
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
Exelixis
Invenra
Flag link:
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Endpoints
Roche
Tecentriq
clinical trials
colon cancer
Exelixis
Cotellic
Flag link:
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Exelixis
Cabometyx
renal cell carcinoma
Flag link:
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Reuters
Pfizer
Exelixis
Cabometyx
kidney cancer
Bosulif
blood cancer
Flag link:
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Motley Fool
Exelixis
Bristol-Myers Squibb
Opdivo
Flag link:
3 Monster Biotech Stocks in the Making
3 Monster Biotech Stocks in the Making
Motley Fool
biotech
Exelixis
Incyte
Vertex Pharmaceuticals
Flag link:
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Investors Business Daily
Amgen
Eli Lilly
JNJ
Exelixis
biotech
Theravance
Bavarian Nordic
Agios
Biohaven Pharmaceuticals
Progenics
Flag link:
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
Flag link:
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Motley Fool
Exelixis
earnings
Cabometyx
Flag link:
Exelixis and Genentech hammer out new deal terms
Exelixis and Genentech hammer out new deal terms
BioPharma Dive
Exelixis
Genentech
Cotellic
melanoma
Flag link:
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
Flag link:
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
Motley Fool
biotech
M&A
Exelixis
Portola Pharmaceuticals
Intercept Pharmaceuticals
Flag link:

Pages